With the American Society for Clinical Oncology annual meeting on the near horizon, cancer is dominating pharma news flow. This week, two FDA approvals brought the spotlight back to a familiar space: immuno-oncology.
Keeping Track: Tecentriq, Opdivo Approvals Intensify Spotlight On Immuno-Oncology
The latest drug development news and highlights from our FDA Performance Tracker.
More from Approvals
Plozasiran, Arrowhead Pharmaceuticals' treatment for familial chylomicronemia syndrome, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
The company’s failure to show its potency assays measured attributes directly related to the mesenchymal stromal cell product’s therapeutic effect highlights the importance of a robust CMC program for complex cell therapies.
Agency staff repeatedly said the BLA based on a single-arm study in 55 patients lacked substantial evidence of effectiveness in steroid-refractory acute graft-versus-host disease and a randomized trial was needed, but changed course “based on additional consideration” after a second CRL.
The Pink Sheet’s Drug Review Profile looks at the timeline for the clinical development and US FDA review of Mesoblast’s remestemcel for graft-versus-host disease.